Literature DB >> 18056172

Stem cell marker nestin and c-Jun NH2-terminal kinases in tumor and peritumor areas of glioblastoma multiforme: possible prognostic implications.

Annunziato Mangiola1, Gina Lama, Cecilia Giannitelli, Pasquale De Bonis, Carmelo Anile, Libero Lauriola, Giuseppe La Torre, Giovanni Sabatino, Giulio Maira, Meena Jhanwar-Uniyal, Gigliola Sica.   

Abstract

PURPOSE: It has been hypothesized that brain tumors are derived from stem cell or transiently dividing precursor transformation. Furthermore, c-Jun NH(2)-terminal kinases (JNKs) have been involved in gliomagenesis. This study analyzes stem cell marker nestin and JNK expression in glioblastoma multiforme (GBM) and peritumor tissue and assesses their possible prognostic implications. EXPERIMENTAL
DESIGN: Nestin and both total JNK (tJNK) and phosphorylated JNK (pJNK) expression was investigated by immunohistochemistry in 20 GBMs. Samples were derived from tumors (first area), from tissues at a distance <1 cm (second area), and between 1 and 3.5 cm (third area) from the macroscopic tumor border. The relationships between patients' age, Karnofsky performance status, gender, protein expression, and survival were analyzed.
RESULTS: Nestin cytoplasmic immunoreactivity was observed in the majority of cells in tumor but infrequently in peritumor areas. tJNK, observed in the nucleus and cytoplasm, was widely expressed in the three areas; pJNK, mostly located in the nuclei, was found in a variable percentage of cells in the tumor and peritumor tissue. Nestin and JNK expression in peritumor areas was independent of the presence of neoplastic cells. Univariate analysis indicated that survival was longer (19 versus 12 months; P = 0.01) for patients whose pJNK/nestin and (pJNK/tJNK)/nestin ratios in the second area were > or =2.619 and > or =0.026, respectively. The same variables showed an independent prognostic value in multivariate analysis.
CONCLUSIONS: Nestin and JNK expression indicates that peritumor tissue, independently of the presence of neoplastic cells, may present signs of transformation. Moreover, pJNK/nestin and (pJNK/tJNK)/nestin ratios in that tissue seem to have some prognostic implications in GBM patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18056172     DOI: 10.1158/1078-0432.CCR-07-1229

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  36 in total

1.  Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A.

Authors:  Christopher G Hubert; Robert K Bradley; Yu Ding; Chad M Toledo; Jacob Herman; Kyobi Skutt-Kakaria; Emily J Girard; Jerry Davison; Jason Berndt; Philip Corrin; Justin Hardcastle; Ryan Basom; Jeffery J Delrow; Thomas Webb; Steven M Pollard; Jeongwu Lee; James M Olson; Patrick J Paddison
Journal:  Genes Dev       Date:  2013-05-01       Impact factor: 11.361

2.  The STAT3 and hypoxia pathways converge on Vasorin to promote stemness and glioblastoma tumorigenesis through Notch1 stabilization.

Authors:  Meiyun Fan; Lawrence M Pfeffer
Journal:  Stem Cell Investig       Date:  2018-10-22

3.  Clinical value of CD133 and nestin in patients with glioma: a population-based study.

Authors:  Rikke H Dahlrot; Steinbjørn Hansen; Stine S Jensen; Henrik D Schrøder; Jacob Hjelmborg; Bjarne W Kristensen
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

4.  Transferrin receptor 2 is frequently and highly expressed in glioblastomas.

Authors:  Alessia Calzolari; Luigi Maria Larocca; Silvia Deaglio; Veronica Finisguerra; Alessandra Boe; Carla Raggi; Lucia Ricci-Vitani; Francesco Pierconti; Fabio Malavasi; Ruggero De Maria; Ugo Testa; Roberto Pallini
Journal:  Transl Oncol       Date:  2010-04       Impact factor: 4.243

5.  Association between EGF +61 G/A and glioma risk in a Chinese population.

Authors:  Shujie Wang; Yao Zhao; Zhenchao Ruan; Hongyan Chen; Weiwei Fan; Juxiang Chen; Qihan Wu; Ji Qian; Tianbao Zhang; Yan Huang; Daru Lu
Journal:  BMC Cancer       Date:  2010-05-21       Impact factor: 4.430

6.  Flow cytometry analysis of neural differentiation markers expression in human glioblastomas may predict their response to chemotherapy.

Authors:  Vladimir Balik; Peter Mirossay; Peter Bohus; Igor Sulla; Ladislav Mirossay; Marek Sarissky
Journal:  Cell Mol Neurobiol       Date:  2009-03-14       Impact factor: 5.046

7.  Neurosphere formation is an independent predictor of clinical outcome in malignant glioma.

Authors:  Dan R Laks; Michael Masterman-Smith; Koppany Visnyei; Brigitte Angenieux; Nicholas M Orozco; Ian Foran; William H Yong; Harry V Vinters; Linda M Liau; Jorge A Lazareff; Paul S Mischel; Timothy F Cloughesy; Steve Horvath; Harley I Kornblum
Journal:  Stem Cells       Date:  2009-04       Impact factor: 6.277

8.  Predictive factors for overall and progression-free survival, and dissemination in oligodendroglial tumors.

Authors:  Masayuki Kanamori; Toshihiro Kumabe; Yukihiko Sonoda; Yoshikazu Nishino; Mika Watanabe; Teiji Tominaga
Journal:  J Neurooncol       Date:  2008-12-20       Impact factor: 4.130

Review 9.  Molecular prognostic factors in glioblastoma: state of the art and future challenges.

Authors:  Ana Xavier-Magalhães; Meera Nandhabalan; Chris Jones; Bruno M Costa
Journal:  CNS Oncol       Date:  2013-11

10.  Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone.

Authors:  Melanie Kappadakunnel; Ascia Eskin; Jun Dong; Stanley F Nelson; Paul S Mischel; Linda M Liau; Phioanh Ngheimphu; Albert Lai; Timothy F Cloughesy; Jonathan Goldin; Whitney B Pope
Journal:  J Neurooncol       Date:  2009-08-05       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.